AZ
AZN
—
NYSE
Pharmaceuticals
Astrazeneca Plc
LatestSun Pharma profit surges 27% on specialty medicine demand
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
2,4k
Day range
—
Prev close
$169,64
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About
AstraZeneca PLC is a global biopharmaceutical company that develops and commercializes prescription medicines, primarily in the oncology, rare diseases, and biopharmaceuticals therapeutic areas.
Business. AstraZeneca PLC (AZN) is a global pharmaceutical company engaged in the research, development, and commercialization of prescription medicines. The firm operates within the Healthcare sector, specifically focusing on the Pharmaceuticals industry and medical research activities. AstraZeneca is headquartered in the United Kingdom and is primarily listed on the New York Stock Exchange. The company generates revenue through the sale of its pharmaceutical products.
Classification78 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY27 analysts
22 buy4 hold1 sell
Avg 12m price target15 961,49
Analyst recommendations
27 analysts · consensus BuyBuy22
Hold4
Sell1
12-month price target
15 961,49
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
27 analysts · indicative
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
6Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,7 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Consumer Discretionary+0,4 %+7,7 %−0,2 %
Information Technology+0,3 %+7,8 %−0,3 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to AZN. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · 2026-07-09
Composite-score breakdown
Synthesis
Business
AstraZeneca PLC (AZN) is a global pharmaceutical company engaged in the research, development, and commercialization of prescription medicines. The firm operates within the Healthcare sector, specifically focusing on the Pharmaceuticals industry and medical research activities. AstraZeneca is headquartered in the United Kingdom and is primarily listed on the New York Stock Exchange. The company generates revenue through the sale of its pharmaceutical products.
Classification78 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
AI synthesis
GENERATED— missing data
Key takeaways
- Financial data is completely unavailable, preventing fundamental valuation or risk assessment.
- Analyst sentiment remains positive with a mean recommendation of 1.85 (buy territory).
- Price targets show a wide dispersion, ranging from 11,300.00 USD to 18,500.00 USD.
- Recent allocator activity suggests increased market attention or coverage updates.
- No segment, geographic, or historical growth data is present to support operational analysis.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$158,25
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
—
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution10 analysts
Strong buy4
Buy6
Hold0
Sell0
Strong sell0
12-month price target$232,34 · Median $232,00
Low $219,00High $250,69
Operating income · consensus21,3B USD
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$11 300,00
Mean$15 961,49
Median$16 300,00
High$18 500,00
Spot$158,25
+9986.3 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskUnknown
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
Source documents
- ASTRAZENECA PLC company facts · 2026-07-27
- allocator_boost (allocator) on AZN · 2026-07-27
- AstraZeneca PLC Market data — analyst estimates · 2026-07-27
- AstraZeneca PLC Market data — ESG · 2026-07-27
Ownership & reference
Insider activity
— missing data
Short positioning
— missing data
Index membership
FTSE 100
OMX Stockholm 30
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
AZNCanonical
NYSE · USD
Intel & risk
What changed
no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)
- Narrative— → —medium
- Business summary— → —medium
- Conclusion— → —medium
- Key takeaways— → —medium
vs prior analysis 34 days ago
peak dispatch · 2026-07-09
OSINT findings
Dilution riskUnknown
Liquidity riskUnknown
Evidence & claims
From filings & derived data- Shares outstanding (quarterly): 1.55BUnknown
- Net income (YoY) (2025-12-31 vs 2024-12-31): 45.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 45.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 19.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 37.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 3.5%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -6.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 45.4%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 4.2%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 46.0%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 9.7%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 4.8%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.34xDerived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 22.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 4.1%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.94xDerived (calculated)
- Return on assets (FY 2025-12-31): 9.0%Derived (calculated)
- Return on equity (FY 2025-12-31): 21.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 9.6%Derived (calculated)
- Operating cash flow (annual): USD 14.57BSEC XBRL filing
- R&D expense (annual): USD 14.23BSEC XBRL filing
- Operating income (annual): USD 13.74BSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 7SEC XBRL filing
- Shareholders' equity (annual): USD 48.72BSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-07-27 11:35 UTCNEWSAstraZeneca maintains profit targets despite clinical setback, ruling out M&A push →
2026-07-27 11:35 UTCNEWSAstraZeneca maintains profit targets despite clinical setback, ruling out M&A push → Management signals organic growth remains the priority after Q2 earnings beat, calming investor fears of dilutive acquisitions.
2026-07-27 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-09 10:37 UTCNEWSAstraZeneca loses £20bn in market value as Wainua heart drug trial fails → The setback in the late-stage cardiovascular study deepens concerns over the pharma giant's pipeline, with shares sliding 11% in London trading.
2026-07-09 07:37 UTCNEWSAstraZeneca shares plunge 9% as heart drug Wainua fails Phase 3 trial → The setback for the experimental treatment, developed with Ionis Pharmaceuticals, removes a potential blockbuster from the pipeline and raises questions about the company's near-term growth trajectory.
2026-07-09 07:15 UTCNEWSAstraZeneca shares plunge after Wainua trial misses primary endpoint → The setback in the transthyretin amyloidosis program casts doubt on the drug's commercial viability, triggering sharp selling in the biotech stock.
2026-07-02 15:41 UTCNEWSOMXS30 hits record highs as Saab and AstraZeneca lead rally → Strong US jobs data lifted sentiment on the Stockholm exchange, with defense and pharma stocks outperforming while Sivers shares fell sharply.
2026-06-23 03:11 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)
2026-05-01 09:56 UTCNEWSAstraZeneca shares fall after FDA panel rejects experimental cancer drug → AstraZeneca stock falls after FDA panel votes against new cancer drug.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage